Ensign Peak Advisors
YMAB

Ensign Peak Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History

Ensign Peak Advisors’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-42,152
Closed -$608K – 2243
2022
Q3 		$608K Hold
42,152
– – ﹤0.01% 1359
2022
Q2 		$638K Buy
42,152
+37,812
+871% +$441K ﹤0.01% 1336
2022
Q1 		$52K Hold
4,340
– – ﹤0.01% 2124
2021
Q4 		$70K Sell
4,340
-1,703
-28% -$36.4K ﹤0.01% 2114
2021
Q3 		$172K Sell
6,043
-16,555
-73% -$522K ﹤0.01% 1764
2021
Q2 		$764K Hold
22,598
– – ﹤0.01% 1508
2021
Q1 		$684K Sell
22,598
-6,750
-23% -$277K ﹤0.01% 1535
2020
Q4 		$1.45M Sell
29,348
-2,831
-9% -$131K ﹤0.01% 1227
2020
Q3 		$1.24M Buy
32,179
+28,398
+751% +$1.13M ﹤0.01% 1214
2020
Q2 		$163K Hold
3,781
– – ﹤0.01% 1600
2020
Q1 		$99K Sell
3,781
-5,020
-57% -$146K ﹤0.01% 1579
2019
Q4 		$275K Buy
+8,801
New +$260K ﹤0.01% 1599

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ensign Peak Advisors's YMAB Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q4 2022, closing a stake of 42,152 shares — an estimated $608K sold.

Ensign Peak Advisors first reported a position in YMAB in Q4 2019 and held it in 12 quarters. The position peaked at $1.45M in Q4 2020. 91 funds tracked by Wall St. Rank hold YMAB as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Y-mAbs Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 42,152 Y-mAbs Therapeutics shares in Q4 2022, an estimated $608K.
  • Ensign Peak Advisors first reported a position in Y-mAbs Therapeutics in Q4 2019 and held it in 12 quarters.
  • Ensign Peak Advisors's Y-mAbs Therapeutics position peaked at $1.45M in Q4 2020.
  • 91 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.